License agreement upfront payment.

No definition available.

Name:	phas_LicenseAgreementUpfrontPayment
Namespace Prefix:	phas_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License Agreements.

+ References

No definition available.

+ Details

Name:	phas_LicenseAgreementsLineItems
Namespace Prefix:	phas_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone Payment

+ References

No definition available.

+ Details

Name:	phas_MilestonePayment
Namespace Prefix:	phas_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Nonroyalty payment received.

+ References

No definition available.

+ Details

Name:	phas_NonroyaltyPaymentReceived
Namespace Prefix:	phas_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Potential milestones payment

+ References

No definition available.

+ Details

Name:	phas_PotentialMilestonesPayment
Namespace Prefix:	phas_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Potential Milestones Payment Receivable

+ References

No definition available.

+ Details

Name:	phas_PotentialMilestonesPaymentReceivable
Namespace Prefix:	phas_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Purchase Obligation, to be Paid, Year Five Through Eleven

+ References

No definition available.

+ Details

Name:	phas_PurchaseObligationToBePaidYearFiveThroughEleven
Namespace Prefix:	phas_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Sale of licensed products or services.

+ References

No definition available.

+ Details

Name:	phas_SaleOfLicensedProductsOrServices
Namespace Prefix:	phas_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Sublicense Agreement, Upfront Payment

+ References

No definition available.

+ Details

Name:	phas_SublicenseAgreementUpfrontPayment
Namespace Prefix:	phas_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of cash outflow for fees classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585

+ Details

Name:	us-gaap_PaymentsForFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of cash paid for royalties during the current period.

+ References

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

No definition available.

+ Details

Name:	us-gaap_PurchaseObligationDueInFourthYear
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of purchase arrangement to be paid in second and third fiscal years following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

No definition available.

+ Details

Name:	us-gaap_PurchaseObligationDueInSecondAndThirdYear
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=phas_DukeUniversityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=phas_WackerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=phas_ViametPharmaceuticalsHoldingsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=phas_BioVectraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=phas_AchievementOfClinicalDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=phas_CommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=phas_AchievementOfCertainPreRevenueRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=phas_AlfasigmaSpAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=phas_AchievementOfCertainCommercialMilestonesAndTieredRoyaltyPaymentsOnNetSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=phas_EMAApprovalOfApplicationForLicensedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=phas_AchievementOfConditionalRegulatoryApprovalFromEMAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=phas_AchievementOfUnconditionalRegulatoryApprovalFromEMAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=phas_PaymentUponAchievementOfCertainDevelopmentAndIntellectualPropertyMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phas_MedImmuneLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=phas_AlfasigmaSpAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Licenses and Other Agreements - Additional Information (Details) - USD ($)	1 Months Ended			3 Months Ended
	Jun. 30, 2021	Jan. 31, 2020	Nov. 30, 2017	Mar. 31, 2022	Mar. 31, 2021
License Agreements [Line Items]
Research and development				$ 14,336,000	$ 22,320,000
Revenue				117,000	0
Purchase obligation, year 2022 through 2023					14,000,000
Purchase obligation, year 2024					37,000,000
Purchase obligation, year 2025 through 2031					48,000,000
Duke University
License Agreements [Line Items]
Aggregate royalties payment				200,000
Sale of licensed products or services				0
Fees payment				300,000
Nonroyalty payment received				1,000,000
Research and development				0	0
Wacker
License Agreements [Line Items]
Research and development				100,000	100,000
Viamet Pharmaceuticals Holdings, LLC
License Agreements [Line Items]
Research and development				0	0
License agreement upfront payment		$ 100,000
BioVectra
License Agreements [Line Items]
Research and development				0	$ 0
Achievement Of Clinical Development And Regulatory Milestones \| Duke University
License Agreements [Line Items]
Potential milestones payment				2,200,000
Commercial Milestones \| Duke University
License Agreements [Line Items]
Potential milestones payment				400,000
Commercial Milestones \| Viamet Pharmaceuticals Holdings, LLC
License Agreements [Line Items]
Potential milestones payment		142,500,000
Achievement Of Certain Pre-Revenue Regulatory Milestones \| Alfasigma S.p.A.
License Agreements [Line Items]
Potential milestones payment	$ 35,000,000
Potential milestones payment receivable	35,000,000
Achievement Of Certain Commercial Milestones And Tiered Royalty Payments On Net Sales \| Alfasigma S.p.A.
License Agreements [Line Items]
Potential milestones payment	190,000,000
EMA Approval Of Application For Licensed Product \| Alfasigma S.p.A.
License Agreements [Line Items]
Potential milestones payment receivable	10,000,000
Achievement Of Conditional Regulatory Approval From EMA \| Alfasigma S.p.A.
License Agreements [Line Items]
Potential milestones payment receivable	12,500,000
Achievement Of Unconditional Regulatory Approval From EMA \| Alfasigma S.p.A.
License Agreements [Line Items]
Potential milestones payment receivable	12,500,000
Achievement Of Certain Development And Intellectual Property Milestones \| Viamet Pharmaceuticals Holdings, LLC
License Agreements [Line Items]
Potential milestones payment		$ 5,100,000
MedImmune Limited
License Agreements [Line Items]
Milestone payment			$ 3,000,000
MedImmune Limited \| Achievement Of Clinical Development And Regulatory Milestones
License Agreements [Line Items]
Potential milestones payment			15,000,000
MedImmune Limited \| Commercial Milestones
License Agreements [Line Items]
Potential milestones payment			$ 50,000,000
Alfasigma S.p.A.
License Agreements [Line Items]
Upfront payment from sublicense agreement	$ 20,000,000
Revenue				$ 10,948,000